InMed's INM-901 Significantly Reduces Neuroinflammation in Alzheimer's Disease Ex Vivo Study

June 24, 2025 7:00 AM EDT | Source: InMed Pharmaceuticals Vancouver, British Columbia--(Newsfile Corp. - June 24, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced new preclinical data demonstrating that INM-901 significantly reduces inflammation in ex vivo models of neuroinflammation, further supporting its potential a ...